Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 févr. 2026 08h30 HE | Source: N2OFF Inc.

N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company

New identity reflects Company’s evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases ...
12 févr. 2026 07h25 HE | Source: N2OFF Inc.

MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases

MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve...
18 nov. 2025 09h12 HE | Source: N2OFF Inc.

N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination

Neve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model,...